Sage Journals: Discover world-class research

Open access

Research article

First published 2025

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

Tjalf Ziemssen, Ann D. Bass, Bart Van Wijmeersch [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2016-8

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024-12

Molecular Mechanism of Sangmei Zhike Granules in Treating Allergic Asthma: Insights from UPLC-MS/MS and Network Pharmacology

Kai Li, Shi-yu Zhang, Gui-rui Huang [...]

Natural Product Communications

Retricted access

Research article

First published 2024-10

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Gloria Dalla Costa, Letizia Leocani, Marco Pisa [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-10

Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination

Elsa Mhanna, Agathe Nouchi, Céline Louapre [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2020-1

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence,detection,and management

Adam Cuker, Ann D Bass, Congor Nadj [...]

Multiple Sclerosis Journal

Retricted access

Other

First published 2010-11

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

SA Morrow, PW O'Connor, CH Polman [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2021-1

CoachMS,an innovative closed-loop,interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study

Valerie J Block, Arpita Gopal, William Rowles [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2025-5

Treating comorbidities in MS is disease modifying: No

Johannes Lorscheider

Multiple Sclerosis Journal

Retricted access

Research article

First published 2022-10

Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients

Gisella Guerrera, Alessandra Mandelli, Annamaria Finardi [...]

Multiple Sclerosis Journal

Search results